USA flag logo/image

An Official Website of the United States Government

Pharmacological Suppression of Rod Opsin as Therapy for Retinitis Pigmentosa

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R43CA171415
Solicitation Year:
2013
Solicitation Topic Code:
NCI
Solicitation Number:
PA12-088
Small Business Information
ORGANIX, INC.
240 SALEM ST WOBURN, MA 01801-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: Pharmacological Suppression of Rod Opsin as Therapy for Retinitis Pigmentosa
Agency: HHS
Contract: 1R43CA171415-01A1
Award Amount: $289,823.00
 

Abstract:

DESCRIPTION (provided by applicant): Metastasis of aggressive breast cancer is a devastating and ultimately fatal condition. The current first- line agents which are used to treat breast cancer metastasis primarily target tumor growth. These drugs produceonly modest increases in survival in patients with aggressive metastatic cancers and have significant side effects. Currently, there are no available treatment options that can specifically and effectively inhibit tumor invasion and metastasis. Therefore,novel drug strategies are needed to treat this chronic, fatal and incurable condition. Our therapeutic strategy for the treatment of aggressive breast cancer is based on reducing Id-1 expression. Id-1 is a key regulator of the invasive and metastatic potential of breast and additional cancers. In this Phase I proposal our focus will be on the optimization of our lead compound to discover one or more analogs that down-regulate Id-1 expression and consequently inhibit breast cancer cell invasion and metastasis. We will also optimize these compounds so that they display a favorable ADME-Tox profile. The ultimate goal of this proposal is to develop a novel therapeutic approach for the treatment of metastatic human breast cancers by down-regulation of Id-1.PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Metastasis of aggressive breast cancer is a devastating and ultimately fatal condition. Currently there are no available treatment options which can effectively inhibit tumor invasion and metastasis. The goal of this proposal is to develop a non-toxic medication for the treatment and prevention of metastatic breast cancer.

Principal Investigator:

Anuradha Mahadevan
781-932-4142
mahadevan@organixinc.com

Business Contact:

Peter Meltxer
781-932-4142
meltzer@organixinc.com
Small Business Information at Submission:

ORGANIX, INC.
240 SALEM ST WOBURN, MA 01801-

EIN/Tax ID: 104293899
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No